ProTransit Nanotherapy, Inc.

ProTransit Nanotherapy is a pre-FDA drug delivery company located in Omaha, NE. Our polymeric nanoparticle technology (called Pro-NP) provides non-toxic, biodegradable, sustained-release of the API and has patent protection until 2035. Current target applications are all topical and focused on anti-aging skincare, sun care, hair regrowth and plaque psoriasis. Small, pre-FDA, IND-approved field trials show remarkable results in topical delivery of antioxidant enzymes to the dermis of the skin and regrowth of hair, far in excess of minoxidil. This platform technology is versatile and can encapsulate a wide variety of APIs. The patent for the SOD/Catalase nanoparticle is granted in the USA and Canada while the hair regrowth and plaque psoriasis applications are in the PCT phase. ProTransit has two funded NIH grants for the use of Pro-NP to 1) treat traumatic brain injury and 2) prevent skin cancer. We are just initiating a Series A round of funding, targeting $20M.